Aesthetic Recall & Safety Alert Watch

The FDA's MedWatch system (fda.gov/medwatch) is the authoritative source for device and drug recalls, adverse event reports, and safety communications. Subscribe to manufacturer alerts directly through your supplier or distributor account (Allergan/AbbVie, Galderma, Evolus, InMode, Cutera, etc.); most send email notifications for material safety events. Check the SEC EDGAR database for 8-K filings from publicly traded aesthetic companies—material events, including safety recalls and regulatory holds, must be disclosed. The American Society of Plastic Surgeons (ASPS) and American Academy of Dermatology (AAD) also circulate safety alerts to members. Set a quarterly calendar reminder to review your inventory against any new alerts; document your review and any actions taken (product pulled, patient notifications sent) in your compliance file.

AbbVie/Allergan Aesthetics has filed multiple material events with the SEC in mid-2026 (June, May, April, July) related to its aesthetic portfolio; the specific nature of these events requires direct review of the SEC filings or company press releases. Evolus (maker of Jeuveau, a neuromodulator) filed material events in July, June, and May 2026, and in March 2026—again, the substance requires direct verification with the company or SEC documents. Galderma announced ongoing regulatory review of its pending Biologics License Application for Relabotulinum toxin A (a competing neuromodulator) with the FDA. Skinvive by Juvéderm (a hyaluronic acid injectable for neck appearance) received FDA approval in 2026 and is now in market; monitor for post-market adverse events. Restylane Contour received FDA approval for temple hollowing in 2026. RHA Dynamic Volume (a hyaluronic acid filler) has been cleared for midface augmentation and age-related volume loss. None of these represent recalls; they are approvals and regulatory milestones. Always verify the current status and any associated safety communications directly with the FDA or manufacturer.

Steel Partners made an unsolicited acquisition proposal for InMode (maker of Morpheus8, Lumenis RF microneedling, and other energy devices) at $16.75 per share in 2026. Ownership transitions and private-equity acquisition can affect product support, software updates, warranty coverage, and service availability. If you own InMode equipment, monitor the deal status and confirm with InMode directly that your devices will continue to receive software updates, spare parts, and technical support post-acquisition. Cynosure Lutronic (owned by Hologic) continues to expand adoption of its XERF monopolar RF device for non-invasive skin tightening; this is a market expansion, not a safety issue, but track it if you are considering RF equipment purchases. L'Oreal increased its stake in Galderma to 20%, signaling continued investment in the company's dermatology and aesthetic portfolio; this is a financial/strategic move, not a safety event.

If a patient experiences an adverse event (infection, allergic reaction, granuloma, vascular occlusion, nerve injury, device malfunction, etc.), you are required to report it to the FDA via MedWatch if it meets the threshold of seriousness (death, serious injury, malfunction that could cause serious injury). Many practices underreport adverse events; this creates a blind spot for the FDA and puts other practices at risk. Document the event in the patient's chart with objective findings, timeline, and treatment. Report to the manufacturer immediately—they have their own post-market surveillance obligations and may issue a safety communication or recall if a pattern emerges. Keep copies of all adverse event reports in a separate compliance file. If a recall is issued, cross-reference your patient roster and inventory to identify anyone who received the product; notify them in writing and offer follow-up care or remediation as appropriate.

The FDA may place a clinical hold on a drug or device if safety or efficacy data raise concerns, or it may delay approval pending additional information. Galderma's Relabotulinum toxin A BLA was under regulatory review in 2026; delays or holds can affect your ability to stock or offer a product. If you have pre-ordered inventory or committed to a product launch and the FDA delays approval, you may face inventory carrying costs or contractual disputes with your supplier. Monitor SEC filings and manufacturer press releases for approval timelines. If a product you rely on faces a hold or significant delay, contact your distributor and manufacturer to understand the timeline and any financial implications. Do not market or sell a product that has not received FDA clearance or approval; doing so violates the Federal Food, Drug, and Cosmetic Act and exposes you to FDA warning letters, injunctions, and civil penalties.

If a product you use is subject to a recall or safety alert, notify affected patients promptly and clearly. A template should include: the product name and lot/serial number (if applicable), the nature of the safety concern, any symptoms or signs they should watch for, and instructions for follow-up (call your office, see your physician, go to the ER if symptoms are severe). Consult your malpractice carrier and legal counsel before sending a recall notice; they may advise on timing, wording, and documentation. Document that you sent the notice (date, method, patient acknowledgment) and keep a copy in the patient's chart and in a separate compliance file. If a patient suffers harm and sues, your documentation of prompt notification and follow-up care is a strong defense. Conversely, failure to notify or delayed notification can be used as evidence of negligence. Do not minimize or downplay the safety concern in your communication; be factual and direct.